Clinical TrialsPub Date : 2026-11-01DOI: 10.1177/17407745261491911
Mark J Giganti, Danni Wu, Theodore Ruel, Elaine J Abrams, Dwight E Yin
{"title":"Revisiting trial design considerations to improve efficiency of HIV-1 vertical transmission prevention efficacy trials in infants.","authors":"Mark J Giganti, Danni Wu, Theodore Ruel, Elaine J Abrams, Dwight E Yin","doi":"10.1177/17407745261491911","DOIUrl":"10.1177/17407745261491911","url":null,"abstract":"<p><strong>Introduction: </strong>While the global incidence of HIV-1 vertical transmission has reduced greatly, a persistent and unacceptable number of new infant infections continue to occur through breastfeeding. Long-acting antiretroviral agents, including injectable drugs and broadly neutralizing monoclonal antibodies, given as prophylaxis to infants hold great potential to eliminate HIV-1 transmission. However, given the low frequency of HIV-1 vertical transmission during breastfeeding in trial settings, efficient and innovative study designs will be necessary to evaluate the efficacy of agents administered to infants as prophylaxis.Key Design Considerations:We provide an overview of study design considerations and assess alternative specifications that may improve the efficiency of future trials to evaluate the efficacy of a novel agent administered to infants in preventing breastfeeding acquisition of HIV-1. We highlight key attributes of the study estimand (intervention, target population, outcomes and endpoints, intercurrent events, and population-level summaries) and discuss nuances in their specification with respect to improving efficiency. We explore alternatives to the classic randomized clinical trial framework, including augmented clinical trials that incorporate external data to supplement clinical trial data. We also provide an overview of Bayesian and transportability-based statistical analysis approaches for analyzing such augmented clinical trials. Modifications to the study design in the context of the estimand framework alone will not be sufficient to address challenges introduced by the low frequency of transmission events. Alternative study designs that incorporate external data are becoming increasingly acceptable and may help alleviate resource constraints.</p><p><strong>Conclusion: </strong>A multi-faceted approach will be required to design efficacy trials for postnatal prophylaxis. This work provides a guide for thinking through key study design decisions.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261491911"},"PeriodicalIF":2.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-29DOI: 10.1177/17407745261501911
Colin B Begg
{"title":"The editor is dead, long live the editor.","authors":"Colin B Begg","doi":"10.1177/17407745261501911","DOIUrl":"https://doi.org/10.1177/17407745261501911","url":null,"abstract":"","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261501911"},"PeriodicalIF":2.4,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-27DOI: 10.1177/17407745261494467
Weilin Wang, Kelley M Kidwell, Robert T Dess, Matthew J Schipper
{"title":"A flexible threshold biomarker trial design for treatment intensification and de-intensification.","authors":"Weilin Wang, Kelley M Kidwell, Robert T Dess, Matthew J Schipper","doi":"10.1177/17407745261494467","DOIUrl":"10.1177/17407745261494467","url":null,"abstract":"<p><strong>Background: </strong>In Oncology, prognostic biomarkers are commonly used to tailor treatment intensity to a patient's risk of disease progression. Several recent Phase III trials embed two studies within one protocol, comparing standard versus de-intensified therapy in good-prognosis patients and intensified versus standard therapy in poor-prognosis patients, using a single fixed biomarker threshold to classify patients into good and poor prognosis. Such designs are clinically intuitive but rely on a prespecified cut-point for which there can be substantial uncertainty as to the optimal value.</p><p><strong>Methods: </strong>We propose a flexible threshold, biomarker-based design in which patients with intermediate biomarker values are randomized to three arms (control, de-intensified, intensified), while those at the extremes are randomized between control and de-intensified therapy (low biomarker) or intensified (high biomarker). The design jointly tests non-inferiority of de-intensified therapy in lower-risk patients and superiority of intensified therapy in higher-risk patients, while estimating the optimal biomarker thresholds. Family-wise Type I error is controlled through a two-stage bootstrap testing procedure.</p><p><strong>Results: </strong>In simulation settings where the alternative non-inferiority and superiority hypotheses hold over broad overlapping biomarker regions, the proposed flexible threshold biomarker design has greater power than a fixed threshold design while maintaining appropriate Type I error control. When the optimal decision rule matches the prespecified fixed cutoff, the two designs perform similarly. This reflects a bias-variance trade-off, in which fixed threshold designs perform well when the cutoff is correctly specified, whereas the flexible threshold biomarker design is more robust when the optimal threshold is uncertain or misspecified.</p><p><strong>Conclusions: </strong>The proposed flexible threshold biomarker design offers a robust and efficient framework for trials seeking to tailor treatment intensity using a prognostic biomarker. The approach is broadly applicable to other diseases in which both escalation and de-escalation of therapy are of clinical interest and there is clinical equipoise among the three treatment options for patients with intermediate biomarker values.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261494467"},"PeriodicalIF":2.4,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13722105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-16DOI: 10.1177/17407745261488336
Ruchi Vaidya, Nayanjeet Chaudhury, Sneha Sewa, Suman V
{"title":"Implementation challenges in a community-based randomized clinical trial in the rural settings of India.","authors":"Ruchi Vaidya, Nayanjeet Chaudhury, Sneha Sewa, Suman V","doi":"10.1177/17407745261488336","DOIUrl":"https://doi.org/10.1177/17407745261488336","url":null,"abstract":"<p><strong>Background: </strong>Community-based randomized controlled trials are the benchmark for evaluating public health interventions due to their real-world relevance. However, their implementation, particularly in resource-limited, rural settings, is challenging. This article details our experience in addressing these hurdles during a nutrition intervention study in rural Karnataka, India.</p><p><strong>Methods: </strong>Our study was a descriptive analysis of the implementation challenges encountered as part of a larger cluster randomized clinical trial among adults with prediabetes residing in rural Karnataka. We analysed challenges encountered during community mobilization, screening, recruitment, data collection, and intervention delivery. A team of six research fellows was rooted in the communities, and a qualitative assurance supervisor conducted weekly field visits to identify and address challenges. In-depth qualitative interviews were conducted with the research fellows, and data were analysed using a thematic content analysis. The study's problem-solving framework was based on agile management principles.</p><p><strong>Results: </strong>We encountered significant challenges related to community mistrust, patriarchal sociocultural barriers, and logistical and operational hurdles. The research team addressed these problems in real time by living within the communities, leveraging the established trust of local health workers, and implementing an agile problem-solving framework. The study's focus on cultural sensitivity and on-the-ground problem-solving was crucial to its high participant retention rate.</p><p><strong>Conclusion: </strong>Our findings highlight the critical methodological and ethical challenges inherent in community-based randomized controlled trials and demonstrate that a flexible, adaptive, and culturally sensitive approach is essential for success in similar settings. The innovative, real-time solutions we developed can be a valuable guide for other community-academic partnerships, providing insights that bridge the gap between scientific protocol and real-world implementation.</p><p><strong>Trial registration number: </strong>The trial is registered in the clinical trial registry of India (CTRI/2023/03/050421).</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261488336"},"PeriodicalIF":2.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-16DOI: 10.1177/17407745261491903
Hayden Farquhar
{"title":"Automated surveillance of primary outcome reporting in clinical trials: Development and validation of a scalable screening pipeline.","authors":"Hayden Farquhar","doi":"10.1177/17407745261491903","DOIUrl":"https://doi.org/10.1177/17407745261491903","url":null,"abstract":"<p><strong>Background: </strong>Detecting discrepancies between registered and published trial outcomes currently requires manual expert review, limiting surveillance to small samples. No scalable automated system exists for continuous monitoring of outcome reporting integrity across the clinical trial literature. We aimed to develop and validate an automated screening pipeline for primary outcome discrepancies and to characterise its performance at scale.</p><p><strong>Methods: </strong>We developed an automated pipeline that retrieves trial registrations from ClinicalTrials.gov, matches them to publications via PubMed and screens for primary outcome discrepancies using a term-matching algorithm. We applied the pipeline to all 46,365 completed interventional trials with posted results (2015-2025) and validated performance against manual expert review of 123 trial-publication pairs, with independent large language model re-review as a second rater.</p><p><strong>Results: </strong>The pipeline processed 46,365 trials in under 48 h, matching 27,555 (59.4%) to publications and confirming 13,595 pairs via trial identifier verification. Automated screening classified 10,231 (75.3%) as concordant and flagged 3353 (24.7%) for review. Against manual review of 123 pairs, the screen achieved 100% specificity and 16.7% sensitivity (1 of 6 discrepancies); the flag's positive predictive value could not be estimated because the validation sample contained only one flagged pair. Independent large language model re-review showed 99.2% agreement (Cohen's kappa = 0.91). Manual review estimated a true discrepancy rate of 4.9% (95% confidence interval = 1.6%-8.9%), predominantly minor modifications (timeframe extensions, operationalisation changes) rather than substantive outcome switching. Automated flag rates were not associated with primary outcome statistical significance (21.0% vs 20.6%; <i>p</i> = 0.745).</p><p><strong>Discussion: </strong>Automated screening can efficiently triage tens of thousands of trials for outcome reporting surveillance, deprioritising 75% of pairs as concordant and concentrating manual review on the flagged subset. The pipeline provides a foundation for continuous, near-real-time monitoring of outcome reporting integrity that could be integrated into journal peer review or regulatory workflows.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261491903"},"PeriodicalIF":2.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-16DOI: 10.1177/17407745261488366
Mojca Cerar, Taylor Coffey, Beatriz Goulão, Katie Gillies
{"title":"Audit and feedback interventions for recruitment and retention in clinical trials: A systematic review.","authors":"Mojca Cerar, Taylor Coffey, Beatriz Goulão, Katie Gillies","doi":"10.1177/17407745261488366","DOIUrl":"https://doi.org/10.1177/17407745261488366","url":null,"abstract":"<p><strong>Background/aims: </strong>This study had two objectives: (1) to determine the effectiveness of audit and feedback interventions for improving recruitment and retention in randomised controlled trials (hereinafter referred to as trials) and (2) to identify and code behaviour change techniques in the reported audit and feedback interventions.</p><p><strong>Methods: </strong>A systematic review was conducted to identify the effect of audit and feedback intervention (alone or in combination) on participant recruitment and/or retention compared to other strategies. Audit and feedback targeting clinical practice was excluded. Embase and MEDLINE databases were searched up to 9 January 2026. Interventions were coded using Behaviour Change Technique Taxonomy version 1. The results are presented in a narrative form.</p><p><strong>Results: </strong>Four studies met the eligibility criteria: three randomised and one non-randomised evaluation. Due to the heterogeneity of interventions and outcomes, a meta-analysis was deemed inappropriate. None of the randomised evaluations demonstrated a statistically significant effect of audit and feedback on recruitment outcomes; the non-randomised study reported an increasing trend in recruitment. The risk of bias was low for one and unclear for two trials. The observational study was at a critical risk of bias. None of the studies applied behavior change techniques explicitly. Twenty-one behavior change techniques were identified at least once across both audit and feedback and co-interventions. Ten behavior change techniques were identified in audit and feedback interventions only (mean = 4.8, standard deviation = 2.4). The behavior change technique identified most often in audit and feedback interventions was '2.7. Feedback on outcome(s) of behaviour' (n = 4, 100%; e.g. emails with league tables describing recruitment performance).</p><p><strong>Conclusions: </strong>This review identified audit and feedback evaluations used to improve recruitment/ retention in a trial context and identified which behavior change techniques are currently used and their frequency. Only one study conceptualised its intervention as audit and feedback and utilised existing audit and feedback literature. Our analysis and behavior change technique coding were restricted to the limited reporting of intervention designs. Further research is needed to understand how audit and feedback is currently being used and whether it can be effective in improving recruitment and retention in trials.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261488366"},"PeriodicalIF":2.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-14DOI: 10.1177/17407745261491900
Peter Doshi, Mark Jones, Kaiser Fung, Linda Wastila
{"title":"Transparency of clinical trials: Reproducing and extending analyses.","authors":"Peter Doshi, Mark Jones, Kaiser Fung, Linda Wastila","doi":"10.1177/17407745261491900","DOIUrl":"https://doi.org/10.1177/17407745261491900","url":null,"abstract":"<p><strong>Background: </strong>Between 2021 and 2023, deidentified patient-level data and associated programming code from the biologics license application for Pfizer's covid-19 vaccine were published on the Internet. The release, which appears to be unprecedented in permitting public access to such granular data, allows new researchers to independently reproduce published analyses and extend published findings by conducting analyses that the original investigators did not report.</p><p><strong>Methods: </strong>We downloaded 2370 files (26 gigabytes), including more than 30 SAS programming files, 2 data reviewer's guides, and 180 SAS Transport datasets from phmpt.org. We documented programming files and adapted them to run in our environment, aiming to reproduce four published tables and a figure reporting efficacy and safety results. We also sought to estimate vaccine efficacy against covid-19 hospitalization, a clinically meaningful and public health relevant measure of potential protection against serious disease that has not been reported.</p><p><strong>Results: </strong>We were able to reproduce 334 of 352 data elements from four published efficacy and safety tables. Lacking original code, we could not reproduce one key efficacy analysis (a cumulative incidence curve). For our extended analyses, we judged that vaccine efficacy against covid-19 hospitalization could not be reliably calculated using the available datasets due to a paradoxical (and therefore unreliable) finding of more covid-19 hospitalizations (n = 43) than cases of severe covid-19 (n = 31).</p><p><strong>Discussion: </strong>The public release of original datasets and patient-level data enabled the exact reproduction of most published efficacy and safety analyses, establishing a firm basis for further analyses. Our experience highlights the feasibility and enormous value of publicly releasing and analyzing patient-level clinical trial datasets.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745261491900"},"PeriodicalIF":2.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-01Epub Date: 2026-04-07DOI: 10.1177/17407745261437363
Maximilian Siebert, Laura Caquelin, Florian Naudet, Joseph S Ross, Reshma Ramachandran
{"title":"Evidence supporting European Medicines Agency drug approvals (2020-2023): A cross-sectional study of trial design and outcomes.","authors":"Maximilian Siebert, Laura Caquelin, Florian Naudet, Joseph S Ross, Reshma Ramachandran","doi":"10.1177/17407745261437363","DOIUrl":"10.1177/17407745261437363","url":null,"abstract":"<p><strong>Background: </strong>The strength and transparency of clinical trial evidence supporting drug approvals have become increasingly scrutinized, particularly considering the increased use of regulatory flexibility and expedited pathways. While US Food and Drug Administration standards have been extensively analyzed, evidence standards at the European Medicines Agency remain less well-characterized. Thus, this study aims to systematically assess the design, quality, and outcomes of pivotal efficacy trials supporting European Medicines Agency drug approvals for new active substances between 2020 and 2023.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of drugs receiving positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use and subsequent approval by the European Commission between January 2020 and December 2023. Data were extracted from European Public Assessment Reports and European Medicines Agency medicine databases. Key variables included trial design features, primary endpoint type and achievement status, and justification for approval in cases of failed efficacy endpoints.</p><p><strong>Results: </strong>Between 2020 and 2023, 227 new drugs were approved by the European Medicines Agency for 234 indications. Of these, 69 (30.4%) were granted orphan designation, and 53 (23.3%) were approved via an expedited pathway, most commonly conditional approval (29 drugs, 12.8%). Cancer was the leading therapeutic area, accounting for 59 approvals (26.0%). Approvals were supported by 404 pivotal clinical trials. Of the 227 drugs, 177 (78.0%) were supported by at least one randomized controlled trial, of which 138 (78.0%) were blinded. Out of those, 139 (78.5%) were supported exclusively by superiority trials. Regarding endpoint classification, 124/227 drugs (54.6%) relied exclusively on surrogate endpoints and 69 (30.4%) on clinical endpoints. Overall, 22 approvals (9.7%) were supported by at least one pivotal trial in which at least one primary endpoint was not met; in five of these cases (22.7%), the failed trial was the sole pivotal trial. The most common rationale for approval despite null primary results was reliance on the totality of evidence, secondary endpoints, or clinical judgment (nine products; 40.9%).</p><p><strong>Conclusion: </strong>Our findings reveal substantial variability in the design and evidentiary strength of pivotal trials supporting European Medicines Agency approvals between 2020 and 2023. While the majority of studies were randomized controlled trials, reliance on surrogate endpoints was common. That 10% of approvals were based on pivotal trials with null primary endpoints highlights the nuanced role of regulatory judgment in therapeutic evaluation. These findings prompt reflection on evolving evidence standards in drug regulation and underscore the need for transparency and consistent justifications.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"490-499"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-01Epub Date: 2026-09-11DOI: 10.1177/17407745261471455
Jonathan Kimmelman
{"title":"New oncology trial designs and equipoise: Commentary on Heynemann et al.","authors":"Jonathan Kimmelman","doi":"10.1177/17407745261471455","DOIUrl":"10.1177/17407745261471455","url":null,"abstract":"<p><p>This essay responds to Heymemann et al.'s analysis of the applicability of clinical equipoise to emerging trial methods in cancer. Briefly, I argue that equipoise presses study designers to conduct trials at the point of maximum community uncertainty. Accordingly, equipoise encourages maximum information gain per patient enrolled (or inversel, minimal patient burden per gain in information). As such, equipoise is as much a condition for the ethical conduct of new study designs as it is for old ones. I close by suggesting that, whereas Heymemann et al. suggest new trial designs present a challenge to the operationalization of equipoise, I argue that equipoise presents a challenge for those wishing to operationalize new trial designs.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"469-471"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical TrialsPub Date : 2026-10-01Epub Date: 2026-04-24DOI: 10.1177/17407745261439661
Daniel F Heitjan
{"title":"Estimating clinical trial hazard functions.","authors":"Daniel F Heitjan","doi":"10.1177/17407745261439661","DOIUrl":"10.1177/17407745261439661","url":null,"abstract":"<p><strong>Background: </strong>Although the analysis of event-based clinical trials commonly relies on assumptions about the underlying hazard functions, in practice it is rare to see estimates of those functions.</p><p><strong>Methods: </strong>I describe conventional and novel methods for estimating the hazard function using discrete and discretized continuous survival models. The conventional approach involves parametric modeling; the novel approach applies Bayesian model averaging to flexible modeling by splines or fractional polynomials. I evaluate the methods in a Monte Carlo study and illustrate them in the analysis of three historical clinical trials.</p><p><strong>Results: </strong>Although flexible models can capture features of the hazard functions-such as multimodality-that parametric models miss, they are not foolproof. Spline modeling was generally the most reliable, in the sense of yielding good coverage probabilities for the mean and median with modest loss of efficiency. In the examples, the discreteness of the measurements-days, weeks, or months-had little effect on the shape of estimated hazard functions. All three data sets showed some evidence of departure from the proportional hazards assumption, but in only one did a test for proportionality detect this departure.</p><p><strong>Conclusion: </strong>Flexible parametric models, estimated in the Bayesian model averaging framework, offer a robust approach to recovering the shape of the hazard function. Analyses of three clinical trial databases suggest that visualization of the hazard function can be a valuable adjunct to conventional survival analysis.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"500-508"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}